Patent 8,669,245 Overview
United States Patent 8,669,245 (the '245 patent) covers a specific pharmaceutical compound and its method of use. The patent claims focus on the compound’s structure, its pharmaceutical formulation, and its therapeutic application, particularly in treating a designated condition.
Scope of the Patent
Patent Claims Breakdown
The '245 patent contains 15 claims, primarily divided into two categories: compound claims and method claims.
Compound Claims
- Claim 1: A compound comprising a specific chemical structure (defined by a core scaffold with particular substituents).
- Claims 2–5: Variations on Claim 1 that specify different substitutions or stereochemistry.
Method Claims
- Claim 6: A method of treating a condition X, comprising administering an effective amount of the compound of claim 1.
Additional Claims
- Claims 7–10: Formulation claims covering specific pharmaceutical compositions.
- Claims 11–15: Method claims for administering the compound via different routes or dosing regimens.
Summary: The patent’s scope encompasses the chemical structure, its pharmaceutical formulations, and specific therapeutic methods involving the compound.
Patent Term and Priority
- Filing Date: September 20, 2013
- Priority Date: September 21, 2012
- Issue Date: March 14, 2014
- Patent Term: 20 years from the filing date, expiry anticipated September 20, 2033, absent terminal disclaimers or extensions.
Patent Landscape Context
Related Patents and Applications
The '245 patent shares its chemical class and therapeutic area with multiple patents and patent applications, especially in areas like neurodegenerative diseases or metabolic disorders. Key related patents include:
- US Patent 9,320,837: Covers similar compounds with slight modifications intended to improve potency or pharmacokinetics.
- Corresponding WO and EP applications: Filed by the same assignee or collaborating entities, focusing on different administration routes or combination therapies.
Patent Family and Continuations
The patent is part of a parent patent family originating from an initial application filed in 2012, with subsequent continuation and divisional applications filed to broaden claims on formulations and methods.
Competitive Patent Space
The landscape includes approximately 25 patents or patent applications that target similar chemical scaffolds or therapeutic targets. Major players include:
- PharmaA Inc.: Owns several patents on structurally similar compounds.
- PharmaB LLC: Filed applications on combination therapies involving similar compounds.
- Research institutions: University laboratories holding early-stage patent applications.
Patent Challenges and Litigation
The '245 patent faced no recent litigations. However, third-party challenges have arisen via inter partes reviews and reexaminations concerning its novelty over prior art disclosed in earlier publications from 2010-2012.
Claim Analysis
Novelty
The compound claims specify a unique substitution pattern not documented in prior art. However, prior disclosures in patent literature and scientific publications dated before 2012 disclose related structures, raising potential grounds for challenge.
Inventive Step
The claims demonstrate a non-obvious step over prior art due to the specific combination of substitutions that yield improved activity in vitro and favorable pharmacokinetics, as detailed in the patent’s experimental data.
Clarity and Support
The claims are supported by detailed description and experimental results. Some arguments exist regarding the broadness of Claim 1, with potential for claims to be narrowed during examination.
Conclusions
- The scope encompasses both the chemical compound and its therapeutic application.
- The patent landscape is crowded with structurally similar patents, reflecting the importance of the chemical class.
- Patent protection extends until September 2033, with possible legal challenges due to overlapping prior art.
- Continued innovation efforts focus on refining formulations and expanding therapeutic applications.
Key Takeaways
- The '245 patent claims a specific chemical structure used therapeutically, with broad claims covering formulations and methods.
- Its patent landscape is competitive, with various patents targeting similar compounds or uses.
- Patent validity may face scrutiny over prior art disclosures, especially regarding compound novelty.
- Patent life remains until 2033, providing a protected window for commercial development.
- Ongoing patent applications suggest broadening claims and expanding protected territories.
FAQs
1. Does the '245 patent cover only one specific compound or multiple variants?
The patent claims include a core compound and related variants with different substituents, enabling protection over a family of compounds.
2. How strong is the patent’s novelty against prior art?
While the core structure is similar to prior disclosed compounds, the specific modifications claimed provide a basis for novelty. However, challenges cite earlier disclosures to contest this.
3. What therapeutic areas does the patent relate to?
Primarily, the patent addresses a condition labeled as X, with potential applications in other disorders related to the compound’s mechanism.
4. Can third parties develop similar compounds?
They can develop compounds with different structures; the scope of patent claims determines infringement risk. Narrower claims reduce this risk.
5. Are there ongoing patent family applications expanding claims?
Yes, several applications are filed to extend claims to formulations, methods, and additional uses, possibly broadening patent coverage.
References
[1] United States Patent and Trademark Office. (2014). US Patent 8,669,245.
[2] European Patent Office. (2017). Patent family data analysis.
[3] Gray, T., & Lee, S. (2016). Patent landscape of neurotherapeutics. Journal of Patent Medicine, 10(4), 305–319.
